Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
72.00    2.00 (2.86%)
Bid:
71.00
Ask:
73.00
Spread: 2.00 (2.817%)
Market Cap: £327.68m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Re Agreement

3 Sep 2007 07:00

Avacta Group plc

Development Contract with the MOD's Defence science and technology laboratory

Field Detection of Liquid Chemicals

Avacta Group plc ("Avacta"), which develops detection and analysis technology aimed at the defence & security, pharmaceutical and clinical diagnostics markets, announces a contract with the Defence science and technology laboratory (Dstl), which is part of the UK Ministry of Defence.

Avacta is developing methods of analysing liquids using laser spectroscopy. The goal is to enable the rapid detection of liquids in the field.

Professor Alastair Smith, Chief Executive, Avacta, commented:

"We are delighted with the new contract for the development of a robust, prototype device. Laser detection and diagnostic devices are a key part of Avacta's portfolio of technologies and this contract with the MOD is an important step for the company."

3 September 2007Enquiries:Avacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk W.H. Ireland Ltd Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Ltd Tel: 020 7099 1942 Michael Brennan/Henry Turcan Notes to Editors:About Avacta

Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address needs in the pharmaceutical, defence and clinical diagnostics markets. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High value solutions in defence and clinical diagnostics are also being provided by Avacta's development programmes. A successful and growing part of the Avacta business model is its technical services arm, Avacta Analytical Ltd which is focused on providing leading edge contract research to the biopharmaceutical and healthcare/personal-care materials sectors. Avacta listed on AIM in August 2006 through the reverse takeover of Readybuy plc which changed its name to Avacta Group plc.

AVACTA GROUP PLC
Date   Source Headline
12th Jul 20214:35 pmRNSPrice Monitoring Extension
29th Jun 20217:00 amRNSAffiDX Lateral Flow Test Detects Delta Variant
28th Jun 202112:13 pmRNSResult of AGM
21st Jun 20212:05 pmRNSSecond Price Monitoring Extn
21st Jun 20212:00 pmRNSPrice Monitoring Extension
21st Jun 20217:00 amRNSAffiDX Lateral Flow Test Distribution Agreement
15th Jun 20218:00 amRNSIssue of Equity and Total Voting Rights
11th Jun 20212:05 pmRNSSecond Price Monitoring Extn
11th Jun 20212:00 pmRNSPrice Monitoring Extension
11th Jun 202111:07 amRNSRegistration of AffiDX Lateral Flow Test in EU
9th Jun 20219:08 amRNSHolding(s) in Company
7th Jun 20217:00 amRNSMHRA Confirms Registration of Lateral Flow Test
1st Jun 20217:00 amRNSUpdate on Lateral Flow Test Regulatory Submissions
28th May 20217:00 amRNSResponse to speculation
25th May 202110:00 amRNSPosting of Annual Report and Notice of AGM
10th May 202110:36 amRNSAffiDX SARS-CoV-2 Antigen Lateral Flow Test Update
6th May 20217:00 amRNSChange of Nominated Adviser
30th Apr 202112:37 pmRNSIssue of Equity
28th Apr 20215:18 pmRNSIssue of Equity
28th Apr 20214:41 pmRNSSecond Price Monitoring Extn
28th Apr 20214:36 pmRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNSFinal Results
20th Apr 202111:05 amRNSSecond Price Monitoring Extn
20th Apr 202111:00 amRNSPrice Monitoring Extension
20th Apr 20217:00 amRNSClinical validation of AffiDX Lateral Flow Test
15th Apr 20214:36 pmRNSPrice Monitoring Extension
13th Apr 20217:00 amRNSNotice of Results and Investor Presentation
12th Apr 20211:30 pmRNSIssue of Equity
6th Apr 20217:00 amRNSDistribution Agreement with ABCAM plc
25th Mar 20213:01 pmRNSDirectorate Change
16th Mar 20215:08 pmRNSIssue of Equity
15th Mar 20215:22 pmRNSIssue of Equity
9th Mar 20217:00 amRNSDiagnostic Licensing Deal with Biokit
8th Mar 20217:00 amRNSRapid Antigen Test Detects SARS-CoV-2 Variants
3rd Mar 20215:14 pmRNSElectronic Communications with Shareholders
24th Feb 20217:00 amRNSBusiness Update
22nd Feb 20217:00 amRNSRe: Press Speculation
18th Feb 20217:00 amRNSPhase I CTA for AVA6000 Approved by MHRA
16th Feb 20219:05 amRNSSecond Price Monitoring Extn
16th Feb 20219:00 amRNSPrice Monitoring Extension
16th Feb 20217:00 amRNSResults of Initial Evaluation of SARS-CoV-2 LFT
8th Feb 20217:00 amRNSCommercial Partnership with Mologic
2nd Feb 20218:30 amRNSIssue of Equity
1st Feb 20217:00 amRNSAffyXell $7.3 Million Series A Financing
29th Jan 202111:00 amRNSIssue of Equity
28th Jan 20217:00 amRNSCollaboration Agreement with Bruker
7th Jan 20217:00 amRNSLicense Agreement with POINT Biopharma Inc.
5th Jan 202111:05 amRNSSecond Price Monitoring Extn
5th Jan 202111:00 amRNSPrice Monitoring Extension
23rd Dec 20207:00 amRNSSubmission of CTA for AVA6000 Pro-doxorubixin

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.